Table 2 Patient characteristics.

From: Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM)

Variable

ITT analysis

Per protocol analysis

Verum (n = 259)

Sham (n = 279)

Total (N = 538)

P

Verum (n = 207)

Sham (n = 231)

Total (N = 438)

P

Age (yr)

40.22 ± 11.62

42.0 ± 12.30

41.14 ± 12.00

0.087

40.64 ± 11.25

40.85 ± 11.84

40.75 ± 11.56

0.847

Gender

Female

214 (82.6)

229 (82.1)

443 (82.3)

0.868

173 (83.6)

191 (82.7)

364 (83.1)

0.804

Male

45 (17.4)

50 (17.9)

95 (17.7)

34 (16.4)

40 (17.3)

74 (16.9)

Headache pain at baseline

No pain

1 (0.4)

0 (0.0)

1 (0.2)

0.532

0 (0.0)

0 (0.0)

0 (0.0)

0.552

Mild

1 (0.4)

0 (0.0)

1 (0.2)

1 (0.5)

0 (0.0)

1 (0.2)

Moderate

155 (59.8)

166 (59.5)

321 (59.7)

125 (60.4)

143 (61.9)

268 (61.2)

Severe

102 (39.4)

113 (40.5)

215 (40.0)

81 (39.1)

88 (38.1)

169 (38.6)

Symptoms at baseline

Photophobia

247 (95.4)

259 (92.8)

506 (94.1)

0.214

198 (95.7)

214 (92.6)

412 (94.1)

0.183

Phonophobia

207 (79.9)

228 (81.7)

435 (80.9)

0.529

164 (79.2)

189 (81.8)

353 (80.6)

0.482

Nausea

169 (65.3)

172 (61.6)

341 (63.4)

0.386

139 (67.1)

144 (62.3)

283 (64.6)

0.293

Vomiting

23 (8.9)

24 (8.6)

47 (8.7)

0.909

18 (8.7)

17 (7.4)

35 (8.0)

0.607

MBS at baseline

Photophobia

162 (62.5)

183 (65.6)

345 (64.1)

0.685

133 (64.3)

149 (64.5)

282 (64.4)

0.469

Phonophobia

38 (14.7)

35 (12.5)

73 (13.6)

28 (13.5)

32 (13.9)

60 (13.7)

Nausea

55 (21.2)

54 (19.4)

109 (20.3)

45 (21.7)

45 (19.5)

90 (20.5)

Vomiting

4 (1.5)

7 (2.5)

11 (2.0)

1 (0.5)

5 (2.2)

6 (1.4)

Migraine with aura

113 (43.6)

111 (39.8)

224 (41.6)

0.366

87 (42.0)

88 (38.1)

175 (40.0)

0.401

Duration of treatment

120.0, 30.0

120.0, 24.0

120.0, 25.0

U = 35,011, 0.463

120.0, 0.0

120.0, 1.0

120.0, 0.0

U = 21,014, 0.002

  1. Categorical data presented as # (%). Normally distributed continuous data presented as mean±SD. Non-normally distributed continuous data presented as median, IQR and a Mann Whitney U test was used to compare groups. MBS most-bothersome symptom.